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This article addresses the evidence that trichloroethylene (TCE) or its metabolites might mediate
tumor formation via a mutagenic mode of action. We review and draw conclusions from the
published mutagenicity and genotoxicity information for TCE and its metabolites, chloral hydrate
(CH), dichloroacetic acid (DCA), trichloroacetic acid (TCA), trichloroethanol, S-(1,2-dichlorovinyl)-
L-cysteine (DCVC), and S-(1,2-dichlorovinyl) glutathione (DCVG). The new U.S. Environmental
Protection Agency proposed Cancer Risk Assessment Guidelines provide for an assessment of the
key events involved in the development of specific tumors. Consistent with this thinking, we
provide a new and general strategy for interpreting genotoxicity data that goes beyond a simple
determination that the chemical is or is not genotoxic. For TCE, we conclude that the weight of the
evidence argues that chemically induced mutation is unlikely to be a key event in the induction of
human tumors that might be caused by TCE itself (as the parent compound) and its metabolites,
CH, DCA, and TCA. This conclusion derives primarily from the fact that these chemicals require very
high doses to be genotoxic. There is not enough information to draw any conclusions for
trichloroethanol and the two trichloroethylene conjugates, DCVC and DCVG. There is some
evidence that DCVC is a more potent mutagen than CH, DCA, or TCA. Unfortunately, definitive
conclusions as to whether TCE will induce tumors in humans via a mutagenic mode of action
cannot be drawn from the available information. More research, including the development and use
of new techniques, is required before it is possible to make a definitive assessment as to whether
chemically induced mutation is a key event in any human tumors resulting from exposure to TCE.
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Trichloroethylene (TCE), an important indus-
trial chemical and widespread environmental
contaminant, is currently undergoing a thor-
ough evaluation and risk assessment by The
National Center for Environmental
Assessment (NCEA) of the U.S. Environ-
mental Protection Agency (U.S. EPA). As a
part ofthis process, NCEA commissioned a
series ofreviews addressing issues ofTCE toxi-
city and the possibility that TCE might pre-
sent a human health hazard. TCE is known to
be a rodent carcinogen and a neurotoxicant
(1). Evaluating the rodent bioassay data for
TCE presents an interesting challenge because
it induces quantitatively different cancer
responses in mice and rats. There is also some
human epidemiological information concern-
ing whether TCE is a human carcinogen (2).
The possible modes ofaction by which TCE
and its metabolites cause biological damage
have been extensively studied. Possible modes
include: somatic cell mutation, the prolifera-
tion ofperoxisome enzymes, cytotoxicity and
reparative hyperplasia, oxidative stress, alter-
ations in calcium ion homeostasis, mitochon-
drial dysfunction, alterations in gene
expression, cell proliferation, (X2u-globin, and
alterations in cell repair. Other articles in this
issue (3,4) explore the possible nongenotoxic
modes of action. Our article addresses the
interpretation of the literature concerning
whether TCE or its metabolites might mediate
tumor formation via a mutagenic mode of
action. We review and draw conclusions from
the mutagenicity and genotoxicity information
published for TCE and its metabolites, chloral
hydrate (CH), dichloroacetic acid (DCA),
trichloroacetic acid (TCA), trichloroethanol,
S-(1,2-dichlorovinyl)-L-cysteine (DCVC), and
5-(1,2-dichlorovinyl) glutathione (DCVG).
Proposed New U.S. EPA
Cancer Risk Assessment
Guidelines
The 1996 proposed revisions to the U.S. EPA
Cancer Risk Assessment Guidelines empha-
size the importance ofmechanistic informa-
tion in conducting a holistic evaluation ofthe
available information for each chemical
undergoing risk assessment. Generally the
available data for cancer induction, following
exposure to a chemical, have been obtained at
doses far exceeding those to which a human
would ever be exposed. In the past, it was
generally assumed that chemicals that cause
cancer at high exposure levels would also
cause cancer at environmentally relevant
exposures and that a linearized multistage
model was appropriate for conducting a
dose-response assessment using the available
tumor data. This practice was based upon the
general understanding that tumors are
induced by chemical genotoxicants and on
the assumption that the process occurred via
linear kinetics.
Under the new guidelines, it is recognized
that there are many factors involved in the
induction of tumors and that cancer can
result via a variety of mechanisms that may
not operate by linear kinetics. The new
process ofcancer risk assessment involves the
identification of key events (key modes of
action) for specific tumor induction. Because
ofthe importance ofmutation in the etiology
of tumors, mutagenicity and genotoxicity
data are used to assess whether mutation is
the, or a, key event by which a chemical
under consideration might induce tumors.
Drawing Proper Conclusions
from Multiple Genotoxicity
Assays
Because ofthe large number ofgenotoxicity
assays, it can be difficult to draw a simple
answer to the question: Is the chemical muta-
genic? Unfortunately, most current analyses
of these large databases are often no more
than a simple assessment as to whether there
is a clear pattern ofpositive data, a clear pat-
tern of negative data, or a combination of
positive and negative data. When there is a
combination of positive and negative data,
often the individual making the evaluation
makes a decision on the basis ofthe relative
number of positives and negatives. On the
other hand, the assessor may call a mixture of
positive and negative responses inconclusive.
Either approach is a mistake and does not
recognize the fact that different assays detect
This article is part of the monograph on Trichloroethylene
Toxicity.
Address correspondence to M.M. Moore, MD 68,
86 Alexander Dr., U.S. EPA, Research Triangle Park,
NC 27711. Telephone: (919) 541-3933. Fax: (919) 541-
0694. E-mail: moore.martha@epa.gov
The authors acknowledge the assistance of D.
Collard, M. Brown-Augustine, and V. Milholland in the
preparation of this review. We also thank Drs. D. Bull,
J. Cogliano, T. DeAngelo, J. Parker, J. Ross, and C.
Scott for their many helpful discussions.
DISCLAIMER. This manuscript has been reviewed
by the National Health and Environmental Effects
Research Laboratory of the U.S. Environmental
Protection Agency and approved for publication.
Approval does not signify that the contents necessarily
reflect the views and policies of the Agency, nor does
mention of trade names or commercial products con-
stitute endorsement or recommendation for use.
Received 20 October 1999; accepted 3 March 2000.
Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000 215MOORE AND HARRINGTON-BROCK
different types ofmutational or genotoxic
damage and that not all published data are of
sufficient quality to be used to make defini-
tive conclusions.
We feel that, with proper interpretation,
much more information can be drawn from
genotoxicity data. In this article, we outline
our strategy for evaluating genotoxicity data
and then apply this approach to the assess-
ment ofwhether mutation is likely to be a
key event in the induction ofTCE-induced
tumors.
We need to emphasize that our approach
to this evaluation represents a new strategy,
and while we feel it provides additional evi-
dence in definingwhether mutation induction
is the (or a) key event in tumor induction, it
does not provide the definitive answer. The
critical question in cancer dose-response
assessment involves understanding the totality
ofthe mode(s) ofaction for aparticular chem-
ical, in the target tissue, and at environmen-
tally relevant exposure levels. Genotoxicity
tests, just like rodent cancer bioassays, are
often conducted at very high exposure levels.
The advantage ofthe genotoxicity tests, how-
ever, is that many of them are sensitive
enough to detect damage at exposure levels far
lower than can be used in the rodent bio-
assays. As described below, we utilize this fea-
ture in drawing conclusions concerning the
possibility that a chemical will be genotoxic at
environmental exposurelevels.
Definition ofGenotoxic and
Mutagenic
Before proceeding further, terminology must
be defined. The term genotoxic iswidely used
and abused. It is used to define chemicals that
cause DNA damage and/or mutations. It is
also used, more narrowly, to define just those
chemicals that form DNA adducts and/or are
positive in the Salmonella bacterial gene
mutation assay. For this review, the term
mutagenic will be used to refer to the demon-
stration that a chemical can induce heritable
mutations (damage that can pass to daughter
somatic cells). Genotoxic will be used in a
broader sense and will include mutational
end points, cytogenetic analysis, and the eval-
uation ofprimary DNAdamage.
Assays That Detect
Genotoxicity but Not
Mutagenicity
The ability ofa chemical to induce primary
DNA damage is assessed in assays that detect
DNA adducts, the analysis ofDNA strand
breakage, and unscheduled DNA synthesis
(UDS). These assays provide evidence that
the chemical can reach the DNA and either
bind to it, cause the chromosomes or DNA
strand(s) to break, or cause the DNA to
undergo an unscheduled period ofsynthesis.
Primary DNAdamage assaysdo notnecessarily
reflect the adverse impact that a chemical
might cause to the cell. While the formation
ofDNA adducts or strand breakage is often
the first step in mutation induction, this
damage can also be repaired. This results in
no damage to the cell, or the cell's repair sys-
tems may be saturated, causing the cell to
invoke a signal transduction pathway result-
ing in programmed cell death. Therefore, it is
important to remember that DNA adducts or
strand breakage assays do not demonstrate
that an agent is mutagenic.
Microscopic analysis of metaphase
chromosomes (cytogenetic analysis) provides
information as to whether a chemical can
cause a change in chromosome number or
break chromosomes, resulting in a variety of
aberrations. While cytogenetic analysis identi-
fies the ability ofthe chemical to cause struc-
tural damage to chromosomes, such damage
may not be compatible with cell survival.
Primary DNA damage information and cyto-
genetic analysis may provide key pieces of
information, but it is much more useful to
know whether a chemical has the ability to
induce DNA or chromosomal damage that
can be passed to daughter cells. This type of
damage, a mutation, is involved in the
process oftumor formation.
Evaluation of Mutagenicity
The induction of tumors is a multistep
process and, at its basis, a genetic, mutational
disease. Mutations become involved in the
etiology ofcancer by chemical (or physical
agent) induction or by increased cellular
growth that provides for an increased sponta-
neous mutation frequency and/or clonal
expansion ofpreexisting mutations. Because
these different processes have different kinet-
ics, understanding the mode(s) ofaction of
specific carcinogens provides insight into the
shape ofthe dose-response curve.
There is a broad array of mutational
damage, from simple point mutation (base
pair changes, insertions, or deletions), to
chromosomal rearrangement (translocations,
mitotic recombination, and gene conversion)
and deletion, to loss or gain ofchromosomes
(aneuploidy), to changes in the whole chro-
mosome complement (polyploidy). Over the
course ofthe past several years, new molecu-
lar techniques coupled with cytogenetic
analysis have revealed that all ofthe various
types ofmutational damage can be involved
in the etiologyoftumors.
When conducting a thorough hazard
characterization for a chemical, it is impor-
tant to determine if that chemical can
induce any ofthe various types ofpossible
mutations. The different mutation hazard
identification assays have different abilities
to detect these changes. The widely used
Salmonella assay detects only a small subset
ofthe possible types ofmutational damage
(point mutations, a few base pair deletions
and insertions). Therefore, chemicals that do
not induce point mutations, yet cause chro-
mosomal mutations oraneuploidy, would be
expected to be negative in the Salmonella
assay and positive in an assay that detects
chromosomal aberrations or chromosomal
mutations. Because it is necessary to evaluate
chemicals for their ability to cause point
mutations and chromosomal mutations, the
Salmonella assay alone is insufficient for
mutation assessment.
There are a verylarge number ofmutation
assays, the majority ofwhich evaluate the
induction ofa mutation at a particular gene.
These assays use a variety ofcells in culture
(primarilybacterial, yeast, fungi, ormammalian
cells) or whole organisms (primarily rodents).
When reviewing, analyzing, and interpreting
genotoxicity data, it is important to recognize
thedifferences amongthevarious typesoftests.
The U.S. EPA-Recommended
Genotoxicity Battery
The U.S. EPA requirements and recommen-
dations for genotoxicity assay selection are
detailed in Dearfield et al. (5). This recom-
mended battery includes the Salmonella
mutation assay, the in vitro mouselymphoma
(thymidine kinase gene) mutation assay, and
an in vivo analysis ofchromosomal damage.
It should be noted that the mouselymphoma
assay, although it uses a single gene as the
selectable marker, detects both gene muta-
tions and chromosomal mutations (6). The
in vivo component ofthis battery is, in fact,
not a mutation assay, but rather a cytogenetic
assay. While not ideal, this selection was
made because ofthe dearth ofappropriate in
vivogene mutation assays.
Integration ofthe Available
Genotoxicity Information
Ideally, a risk assessment to determine a
chemical's mutagenic potential should be
based on a complete data set. Unfortunately,
unless the chemical evaluation is done in a
systematic manner, specifically for risk assess-
ment, notall the critical information is gener-
ally available. In such situations, it is
important to remember that lack ofinforma-
tion does not equate to lack ofactivity. That
is, ifthere are little or no available data, it is
incorrect to say that there is no evidence that
the chemical is mutagenic. Rather, it is cor-
rect to say that there is no information as to
thepossible mutagenicity ofthechemical.
When there is information from multiple
assays and end points, how should those data
be weighed and integrated? The answer
depends upon the question being asked.
When, as for TCE, the goal is to provide
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insight into the cancer dose response, one of
the key pieces ofinformation is whether the
TCE-induced tumors result from TCE-
induced mutations. In the absence of this
information (due to the lack of adequate
techniques), data that define the genotoxicity
or mutagenicity ofTCE (or its metabolites)
in the target organ should receive the most
weight. Ofnext importance is the definition
ofthe in vivo (nontarget tissue) mutagenicity
ofthe chemicals. It should be emphasized,
however, that there are currently no tech-
niques that can completely define the non-
mutagenicity ofa chemical in vivo in either
target or nontarget tissue. The techniques
that can be used in vivo to detect mutational
damage do not cover the full range ofpossible
mutations important in the etiology of
cancer. At a minimum one needs to deter-
mine ifthe chemical can induce either point
mutations or chromosomal damage. Presently
this must be done using both gene mutation
and cytogenetic assays. While there are some
gene mutation assays that can be applied to
target tissue, cytogenetic analysis is generally
not possible. Only in rare situations (as with
DCA-see below) is there both in vivo gene
mutation (in this case in target tissue) and
cytogenetic data (in this case in bone mar-
row). Therefore, while in general one might
like to assign less weight to in vitro informa-
tion, such information is still critical in the
overall assessment. Thus, chemicals that are
not mutagenic in vivo, yet are clearly demon-
strated to be mutagenic in vitro, should not
automatically be ruled as nonmutagenic.
Generally, mutagenicity data should
receive moreweight than primary DNA inter-
action data. One exception is when the pri-
mary DNA interaction data are obtained in
vivo and in the target organ. Positive data
obtained using the target tissue provide pow-
erful evidence that the chemical or its meta-
bolite reached the DNAin the target organ.
Ofcourse, these various assays provide
information as to whether a chemical has the
potential to be genotoxic or mutagenic. They
do not provide definitive information as to
whether the chemical induces tumors by a
mutagenic mechanism. In fact, with the cur-
rently available techniques, it is not possible
to condusively determine whether a tumor is
induced via a chemically induced mutational
mechanism. At best, one can consider the
available information and evaluate the likely
mechanisms.
Use ofGenotoxicity/
Mutagenicity Data in
Dose-Response Assessment
Genotoxicity data provide information
concerning a chemical's potential to cause
mutational damage and, in the context of
cancer riskassessment, thepotential to mediate
that tumor formation through a mutational
mechanism. Historically, in the risk assessment
arena, mutagenic carcinogens were assumed to
induce tumors with linear dose-response
kinetics and thus not to have thresholds or
shallow initial dose-response curves resem-
bling thresholds. This is not, in fact, a good
assumption. There are many theoretical rea-
sons why mutagenic carcinogens might have
nonlinear dose-response curves. The low-dose
linear default assumption is based on the
assumption that mutations are induced by
one-hit kinetics and that even one molecule of
the chemical has the potential to be muta-
genic. Observed during earlystudies with radi-
ation, one-hit kinetics occur when one
chemical interaction with the DNA results in
one mutation. It has long been known that
chromosomal mutations, such as interstitial
deletions involving multiple base pairs and
translocations, require two hits (two chemical
interactions) with the DNA or chromosome
and thus have nonlinear dose-response curves.
For chemicals acting primarily by inducing
chromosomal mutations with two-hit kinetics,
a linear extrapolation from data obtained at
high dose levels will greatly overestimate the
riskatlowdose levels.
Furthermore, the shape of the dose-
response curve for mutagenic carcinogens is
not driven solely by the kinetics by which a
chemical and/or its metabolite(s) induces
mutations relevant to tumor formation. In all
cases the chemical must, at aminimum, reach
the target organ(s). Most chemicals are
metabolized, and this is often a prerequisite
to mutagenicity or carcinogenicity. The
kinetics by which a chemical moves through
the organism and is metabolized and distrib-
uted in the tissues is likely to strongly affect
the shape ofthe tumor or mutation dose-
response curve.
Often rodent cancer bioassays require
relatively high doses ofchemicals over long
time periods to induce tumors. Because the
biological consequences ofmechanisms active
at these high doses may be different from
those ofmechanisms active atlowerdoses, it is
possible that tumors may be induced only at
these high doses and that lowdoses may result
in no tumor formation. Alternatively, the
shape ofthe tumor dose-response curve may
be very different at high and low doses. Like
tumors, mutations also can be induced athigh
doses by mechanisms that are not operational
at lower doses. Aproperlyconducted genotox-
icity evaluation battery oftests will provide
some insight into the ability ofa chemical to
induce mutations across a full dose range.
This issue is particularly important in predict-
ing the likely shape oftumor dose-response
curves at environmentally relevant exposure
levels. Chemicals that induce mutations only
athigh doses (or are nonmutagenic) arehighly
unlikely to have linear tumor dose-response
curves across all exposure levels.
Review of Data for TCE
and TCE Metabolites
As stated above, genotoxicity data provide
evidence concerning the potential for a chem-
ical to mediate cancer through a mutational
mechanism. Unfortunately, it is impossible at
present to determine whether tumors are
actually mediated by chemically induced
mutations. The DNA sequence analysis of
mutations present in tumor tissue can, in
some situations, provide insight into this
issue, and there is some DNA sequence infor-
mation available for TCE and its metabolites
DCAandTCA.
This article reviews the genotoxicity infor-
mation for TCE and for its metabolites. Each
chemical is addressed and summarized sepa-
rately. In each case, available data are evaluated
to determine the likelihood that the chemical
is mutagenic, and also whether the chemical is
likely to be mutagenic at environmentally rele-
vant doses. This assessment is made byconsid-
ering the magnitude ofthe dose required to
show any observable genotoxic effect. As will
be seen below, the doses required forTCE and
its metabolites to induce any genotoxicity are
generally orders ofmagnitude higher than one
would expect to occur in a target organ. The
differences between the rodent and human
metabolism ofTCE and the differences in the
concentrations ofthe various metabolites in
the target tissues are important factors in the
interpretation ofthe probable mode ofaction.
This information is well detailed by other
authors in this series ofpapers (3,4,7).
Following the individual chemical evalua-
tions, the information is integrated to provide
an assessment ofall the available genotoxicity
information and how it relates to the poten-
tial TCE human cancerhealth risk.
Trichloroethylene
Trichloroethylene has been extensively
studied for potential genotoxicity and muta-
genicity. Because there are extensive reviews
summarizing this body ofliterature (8,9),
only a summary ofthe data and their inter-
pretation will be presented. Taken together,
evidence from a number ofdifferent analyses
and a number ofdifferent laboratories using a
fairly complete array ofend points indicates
that TCE may have the potential to be both
genotoxic and mutagenic. However, the evi-
dence that TCE is mutagenic is not convinc-
ing and is somewhat confounded by the fact
that TCE is often stabilized with a very low
concentration ofepichlorohydrin or 1,2-
epoxybutane, both known to be potent muta-
gens (10). Available evidence indicates that if
TCE is genotoxic/mutagenic, it must be
metabolized to induce geneticdamage.
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The most relevant observations from the
genotoxicity and mutagenicity information
are summarized below. In assays that evaluate
the ability of the chemical to interact or
directly damage DNA, there is evidence that
metabolites of TCE can bind to DNA
(11,12). Ofparticular interest with regard to
the observed differences between the mouse
and rat following TCE exposure, Miller and
Guengerich (12) found that when treated
with TCE, isolated mouse hepatocytes
showed severalfold higher DNA adduct levels
than isolated rat hepatocytes. In some studies
TCE appeared capable of inducing point
mutations (8). However, in a series of care-
fully controlled studies evaluating TCE
(without the mutagenic stabilizers),
McGregor and co-workers (10) found TCE
incapable of inducing point mutations in
Salmonella. Therefore, it is unlikely that TCE
induces point mutations.
There is some evidence that TCE may be
a weak inducer ofother types ofmutational
damage, including mitotic recombination
and aneuploidy (13-15). Technical deficien-
cies in the conduct ofthe in vitromammalian
cell mouse lymphoma assay (no colony siz-
ing) limit the usefulness ofthe in vitro mam-
malian data (16). In vitro gross chromosome
aberration analysis using Chinese hamster
ovary cells found TCE to be negative both
with and without exogenous activation (17).
In vivo, however, there is some evidence that
TCE or its metabolites can bind to DNA in
hepatic and kidney cells, and that it can also
induce single-strand DNA breaks in both
hepatic and kidney cells (11,18). Some
species differences were observedwhen single-
strand DNAbreakage was analyzed in hepatic
cells by alkaline unwinding. Mice required
less TCE exposure to cause single-strand
DNAbreaks than rats (18,19). There is some
evidence that TCE can induce bone marrow
cell micronuclei in rats but not mice, but
unfortunately the study was compromised by
TCE PER ° S -01Jo !
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Figure 1. A comparison of the capacity for induction of
single-strand breakage (SSB) in liver DNA of mice
treated with different agents. The values were deter-
mined 1 hr after injection and were normalized to 1
mmol/kg/ body weight. The induced level of SSB is
expressed for TCE, PER, styrene, styrene-7,8-oxide, and
MMS. All data are from Walles(19).
high negative controls in one (rat) data set,
which prevented the confirmation ofthe rat
response (20). TCE was weakly active in the
mouse spot test, which determines the ability
ofchemicals to induce gene mutations or
recombination in loci governing the color of
the animal's coat (21). Several investigations
have involved humans occupationally
exposed to TCE (22,23). Sister chromatid
exchange (SCE), aneuploidy, and chromo-
some aberrations in peripheral lymphocytes,
as well as sperm morphology have been ana-
lyzed (24-27). No clear positive effects have
been observed in these human studies, but all
of the studies have one or more technical
deficiencies. Given the number of studies
conducted, however, ifTCE were a potent
inducer ofgenetic damage in peripheral lym-
phocytes, it is likely that damage would have
been observed.
An evaluation ofthe potential genotoxic
potency ofTCE shows that the dose ofTCE
required to give any positive responses is gen-
erally very high. In the various assays in
which TCE has been evaluated, the concen-
tration required to see mutagenicity is very
high relative to the concentration required for
other chemicals to showgenotoxicity. That is,
the assays used are capable of detecting
responses at doses orders ofmagnitude lower
than required to see TCE activity. The
studies ofWalles (19) help put the potencyof
TCE for inducing DNA single-strand breaks
in the livers of male mice into perspective.
Using intraperitoneal (i.p.) injection and the
DNA unwinding technique, researchers com-
pared the capability ofmethylmethanesul-
fonate (MMS), styrene-7,8-oxide, styrene,
perchloroethylene, and TCE for inducing sin-
gle-strand DNA breaks (19). From this study
(Figure 1) it is clear that even at the very high
doses used, 4-10 mmol ofTCE/kg body
weight, TCE induced only very low levels of
DNA breakage. The absence ofDNA break-
age at lower exposure levels argues that very
high exposure levels ofTCE must be attained
before it is able, either directly or through its
metabolites, to break DNA. It is unlikely that
these exposure levels would ever occur in
humans exposed to TCE.
In summary, in those genotoxicity assays
in which positive responses were seen follow-
ing TCE exposure, the activity generally was
weak, even at very high doses. It also appears
that TCE itselfhas little, ifany, mutagenic
potential; any mutagenic activity resulting
from TCE exposure likely results from one or
more ofits metabolites.
ChloralHydrte
Chloral hydrate has been extensively studied
as a potentially genotoxic agent. It has been
evaluated in the recommended genotoxicity
screening battery and several other assays
including genetic alterations in rodent germ
cells. CH was positive in bacterial mutation
tests, indicating that it may be capable of
inducing point mutations (28-30). It was
positive in the mouse lymphoma assay for
mutations at the Tk locus (31). The mutants
were primarily small colonyTk mutants, indi-
cating that most CH-induced mutants
resulted from chromosomal mutations rather
than point mutations. In other in vitro assays,
CH induced micronuclei in Chinese hamster
embryonic fibroblasts (32), Chinese hamster
pulmonary cell lines Luc2 and Don.Wq.3H
(33), and human peripheral blood lympho-
cytes (34). Aneuploidy induction (assessed as
kinetochore positive micronuclei) was
observed in Chinese hamster Luc2 cells (35)
and human peripheral blood lymphocytes
(36). Chromosome aberrations were found in
Chinese hamsterembryonic diploid cells (37).
Because there is a mixture ofpositive and
negative in vivodata, with no reason to weigh
some studies more than others, it is not clear
whether CH is capable of inducing genetic
damage in vivo. Russo and Levis (38) found
CH to be capable ofinducing aneuploidy in
mouse spermatocytes. Two different research
groups reported an increase in micronuclei in
mouse spermatids when treatment involved
exposure ofspermatogonia stem cells (39,40,)
and Russo et al. (41) found CH to induce
micronuclei in mouse bone marrow erythro-
cytes. Other studies, however, found CH to
be negative in in vivo experiments (42,43),
and a study with mouse oocytes also found
CH to be negative (44).
Although CH can induce a variety of
mutational events, it does so with a very low
potency. Figure 2 shows the relative potency
in the Salmonella assay for CH and other
metabolites ofTCE. Its relative potency for
inducing micronuclei is shown in Figures 3
and 4. The data in Figures 3 and 4 were gen-
erated as a part ofthe European Communities
collaborative study to evaluate a number of
assays for their ability to detect aneugens.
Figure 3 shows the comparative data from
Ferguson et al. (36), using human peripheral
blood lymphocytes; Figure 4 shows the data
from Lynch and Parry (35), usinglow-passage
Chinese hamster Luc2 cells. In both cases, the
number ofmicronuclei induced by CH was
relatively low and the concentration required
to induce that effect quite high. In the in vitro
mouse lymphoma assay, capable ofdetecting
almost the complete spectrum ofmutational
events, CH was one ofthe least potent muta-
gens evaluated (Figure 5).
The comparative potency data (Figures
2-5) are provided to emphasize the evidence
that the mutagenic activity ofCH is likely a
high-dose effect. As shown clearly in these fig-
ures, the Salmonella assay, the micronucleus
assays, and the mouse lymphoma assay can
Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000 218MUTAGENICITY OF TCE AND ITS METABOLITES
respond to reflect the genetic activity of
chemicals at doses much lower than were
active for CH. Stated another way, if CH
were genotoxic at lower levels, these assays
would have detected that activity. In all of
these in vitro assays, the concentration ofCH
required to see a positive response was over
500 pglmL, a concentration likely several
orders ofmagnitude greater than would ever
be reached in vivo in a target tissue.
Therefore, we conclude that it is unlikely that
anyTCE-induced tumors would be mediated
through mutations induced byCH.
DichioroaceicAcid
The standard genotoxicity screening battery
found DCA to be mutagenic. In Salmonella
typhimurium strain TA 100, S9 enhanced the
activity ofDCAsignificantly when the vapor-
ization (Tedlar bag) technique was used (46).
Evidence that DCA can induce point muta-
tions is strengthened by the DeMarini et al.
(46) observation that the molecular spectrum
of mutants in DCA-treated cultures was
different from that ofuntreated cultures.
DCAwas mutagenic in the in vitromouse
lymphoma assay (31), inducing primarily
small colony mutants (indicating chromoso-
mal mutations). These researchers also found
DCA to be clastogenic in vitro to mouse lym-
phoma cells. Fuscoe et al. (52) utilized a
drinking water route ofadministration with
DCA in vivo, and determined that DCA
induced a very small increase in the number
ofbone marrow micronuclei when animals
were exposed to concentrations similar to
those used in the rodent bioassay.
DCA can cause DNA strand breaks in
mouse and rat liver cells following in vivo
administration by gavage (18). Interestingly,
the DNA strand break dose-response curves
differ between mouse and rat. Fuscoe et al.
(52), using the single-cell gel (orcomet) assay,
reported crosslinking in blood leukocytes in
mice exposed to 3.5 g/L DCA for 28 days. As
discussed, primary DNA damage assays,
although useful in determining the ability ofa
chemical to reach the target tissue and interact
with the genetic material, do not prove that
thechemical can cause mutational damage.
More informative with regard to the
possibility that DCA can cause mutations in
liver cells is the study using the Lac I locus in
the Big Blue mouse (53). These investigators
used a drinking water route and the same
doses of DCA that cause tumors in rodents.
Mice treated with 3.5 g/L DCA for 60 weeks
had a 2.3-fold increase in mutant frequency
over the concurrent controls. Mutational
spectral analysis ofthese mutants (in which
approximately 1,400 base pairs were analyzed
for possible mutation) revealed a different
spectrum in the mutants in DCA-treated
animals than was seen in the untreated
animals, indicating that the mutations were
likely induced by the DCA treatment. Also
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Figure 2. Mutagenicity of TCE metabolites in Salmonella strains TA100 and TA2638.
DCVC A and DCVG * were evaluated using strain TA2638; data from Vamvakas et al.
(45). DCA a and TCA v were evaluated using a vaporization technique in Salmonella
TA100; data from DeMarini et al. (46). CH 0 was evaluated in strain TA100; data from
Haworth et al. (29).
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Figure 4. Comparative micronucleus induction in low-passage Chinese hamster Luc2
cells. Chloral hydrate *; colchicine *; vinblastine A; thiabendazole *; diazepam o;
pyrimethamine v; cadmium chloride *; and mitomycin C 0. All data are from Lynch
and Parry(35).
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Figure 3. Effects of various compounds on the frequency of micronuclei in cytokinesis-
blocked human peripheral blood lymphocytes; colchicine *; chloral hydrate *;
diazepam 0; econidazole A; hydroxoquinone *. Data are from Ferguson etal. (36).
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Figure 5. A comparison of Tk mutant frequencies after treatment of L5178Y/Tk+/--
3.7.2C cells with m-amsacrine *, DeMarini et al. (50); 3-chloro-4-(dichloromethyl)-5-
hydroxy-2[5H]-furanone (MX) A, Harrington-Brock et al. (47); Arsenic x, Moore et al.
(48); 2-acetylaminofluorene *, Harrington-Brock (51); ethylmethansulfonate *, Moore
et al. (49); DCA *, CH *, and TCA 0, Harrington-Brock etal. (31).
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of significance, the types of mutations
observed were similar to those previously
seen in codon 61 ofthe H-ras gene ofliver
tumors from mice treated with DCA (see
further discussion below).
At the high dose ofDCA, a large portion
of the liver may actually be tumor tissue.
Every attempt, however, was made to use
only normal tissue rather than tumor tissue
for the analysis (54). These precautions were
taken because tumors result from clonal
expansion, and the presence oftumor tissue
in the sample evaluated would give a falsely
high mutant frequency ifa Lac I mutation
occurred in the rapidly expanding tumor
clone. The investigators were able to elimi-
nate the possibility that clonal expansion
played a significant role because the DNA
sequence analysis demonstrated that almost
all ofthe mutations were unique.
When all ofthis DCA information is inte-
grated, it is dear that DCA is mutagenic but
only very weakly mutagenic. This conclusion
is based on comparing the potency ofDCA
and other chemicals in the Salmonella assay
(Figure 2), the in vitromouse lymphoma assay
(Figure 5), and in vivo for micronuclei induc-
tion (Figure 6). In all three ofthese assays,
DCA is one ofthe least potent mutagens that
have been evaluated. Furthermore, in the Big
Blue mouse system, the amount of DCA
required to induce a very small mutagenic
response isveryhigh (Figure 7).
As can be clearly seen in Figures 6 and 7,
the in vivo assays are capable ofdemonstrat-
ing substantial responses at doses much lower
than were required for DCA. Therefore, if
DCAwere capable ofinducinglarge amounts
ofgenotoxic (or mutagenic) damage, this
could have been detected in either ofthe in
vivo assays. Therefore, while one cannot
eliminate the possibility that DCA might
induce tumors via a mutagenic mode of
action, we feel that theweight ofthe evidence
argues that any TCE-induced tumors would
not be mediated byDCA-induced mutation.
TrichioroaceticAcid
Trichloroacetic acid is the least mutagenic of
the TCE metabolites discussed so far. It was
negative in Salmonella (46) (Figure 2). TCA
was weakly positive in the mouse lymphoma
assay. However it was one ofthe very least
potent mutagens (Figure 5) identified in the
assay (31) and was substantially less muta-
genic than either DCA or CH. It is unclear
whether TCA can induce chromosomal dam-
age in vivo, because some studies have seen
positive responses and others negative. Nelson
and Bull (18) and Nelson et al. (59) found
TCA to break hepatic DNA strands, and
Bhunya and Jena (60) and Birner et al. (61)
found TCA to be genotoxic in mouse and
chick test systems. In contrast, Mackay et al.
(62) used a neutralized form ofTCA and
found that TCA does not induce chromo-
some damage in human lymphocytes in vitro
or in the bone marrow micronucleus test.
These results with the neutralized TCA sup-
port the observation that TCA is nonclasto-
genic (63) and the negative results obtained
by other researchers (64,65). It is therefore
unlikely that TCAwould contribute to tumor
formation through amutational mechanism.
Trichioroetbanol
Trichloroethanol was negative in the
Salmonellaassay (46) but has not been evalu-
ated in the other recommended screening
assays. As noted already, the Salmonella assay
detects only a small subset ofthe possible
types of mutations. One cannot conclude
that a chemical is nonmutagenic until it has
been evaluated in assays that detect chromo-
somal mutations. The potential of tri-
chloroethanol as a mutagen, therefore,
remains unknown.
TrichoroethyleneConjugates
DCVC and DCVG are capable ofinducing
point mutations, as evidenced by their muta-
genicity in bacteria (45,66). DCVC is the
most potent of the TCE metabolites as a
Salmonella mutagen (Figure 2), while DCVG
appears to be substantially less potent and is
similar in potency to DCA. DCVC is a
metabolite ofDCVG (7), and based on the
Salmonella data, might be argued to be the
most active ofthe metabolites.
It should be noted that the data shown in
Figure 2 represent results in two different
Salmonella tester strains. This creates some-
what ofa compromise in the interpretation of
the data. DCVC and DCVG were evaluated
in TA2638, a strain with increased metabolic
capacity. The other chemicals, DCA, TCA,
and CH, were not evaluated in TA2638 but
ratherwere evaluated in TA100, a strain lack-
ing the increased metabolic capacity.
Therefore, there is some possibility that
DCA, TCA, and CH could, in fact, be more
potent in a bacterial point mutation system
thanwould be indicated byFigure 2.
Unfortunately, there is no genotoxicity
information for DCVC and DCVG in the
other recommended screening tests. There is,
however, some indication that DCVC can
induce primary DNAdamage in mammalian
cells in vitro and in vivo (67,68). In a Syrian
hamster embryo fibroblast system, DCVC
gave a comparatively weak UDS response
and no induced micronucleus formation
(69). In addition, Vamvakas and Koster (70)
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Figure 6. Acomparison ofthe induction ofmicronucleated polychromatic erythrocytes in
peripheral blood of mice. Male B6C3F, mice were treated with 1.0, 2.0, and 3.5 g/L of
DCA a in drinking water(9days adlibitum). Data shown are calculated total dosesfrom
Fuscoe et al. (52). Male B6C3F, male mice received 3 i.p. injections of benzidine v and
7,12-dimethylbenzanthracene A. Data shown are calculated total doses from Tice et al.
(55). Male Swiss-Webster mice received a single i.p. injection of either triethyleneme-
lamine 0, mitomycin C *, orcolchicine *; data are from MacGregor etal.(56).
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Figure 7. A comparison of mutant frequencies induced in liver cells of Big Blue trans-
genic mice. Urethane * was administered in the feed for 105 days; data from
Shephard et al. (57). Dimethyinitrosamine (DMN) 0 was administered i.p. for 5 days;
data from Mirsalis et al. (58). DCA A was administered in the drinking water at 1.0g/L
and 3.5 g/L for 4, 10, or 60 weeks; data shown are from Leavitt et al. (53) with total
cumulative dose data provided by DeAngelo (77).
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have shown that DCVC can induce the
expression of two protooncogenes, c-fos and
c-myc. It is unknown whether this alteration
in gene expression might be involved in
tumor induction.
In summary, DCVC (a metabolite of
DCVG) is the most potent bacterial mutagen
ofthe TCE metabolites. Because there are no
data for mammalian cells from in vitro or
in vivo experiments, the genotoxic potency of
DCVC and DCVG is unknown.
Analysis of Mutational Spectra
in Tumors
As stated in the introduction, the key
question is whether TCE-induced tumors are
mediated through an induced mutational
mechanism. That is, is chemically induced
mutation a key event in the induction of
TCE tumors, or do tumors arise primarily
through some other mode ofaction such as
increased cell proliferation, which serves to
increase the spontaneous mutation frequency?
The kinetics ofthese two modes ofaction
would be very different, and thus this distinc-
tion is critical for dose-response assessment.
Several research groups (65,71,72) investigat-
ing the etiology of mouse liver tumors in
untreated and chemically treated animals
have analyzed mutations in the ras oncogene
oftumor tissue. All ofthese studies reported
that approximately 50% ofthe tumors from
either untreated or treated animals had a
mutation in either K-ras or H-ras. For
instance, in the Ferreira-Gonzalez et al. (65)
study, 45-50% of the tumors from DCA-
treated animals showed mutations in Exon 1,
2, or 3 ofH-ras or K-ras. In the Anna et al.
study (71), 59% ofthe tumors from DCA-
treated animals showed mutations in H-ras
codon 61. Untreated animals show very simi-
lar percentages of H-ras mutations in their
tumors, with these two studies reporting 58
and 54%, respectively. It is therefore impor-
tant to note that K-ras or H-ras mutation is
obviously not required to induce tumors and
that other events are important, and may be
rate limiting, either in addition to or instead
ofrasgene mutation.
Both Anna et al. (71) and Ferreira-
Gonzalez et al. (65) compare the mutations
seen at codon 61 of H-ras in treated and
untreated animals (Table 1). Because the
number oftumors analyzed in these studies is
very small, information from Maronpot et al.
(72,73) is presented in Table 2. In the
untreated animals in these four studies,
52-62% of the mutations are to AAA;
26-36% are to CGA; and 10-12% are to
CTA. For animals treated with TCE, the
number of mutants that are AAA is much
lower and the number of CTA mutants is
much higher than in untreated animals.
Animals treatedwith DCA show adecrease in
AAA mutants and an increase in CGA and
CTA mutants. The TCA-treated animals
show a slight increase in the AAA mutants
and no CTA mutants. However, in all cases,
particularly for TCA, the number ofmuta-
tions analyzed is relatively small. In fact, for
TCA only five mutants were analyzed, mak-
ing it difficult to draw any valid conclusions.
Taken together these data suggest that the
percentage ofthe specific point mutations is
different in the tumors from DCA- and
TCE-treated animals. While it could be
argued that this is consistent with a chemi-
cally induced mutational mechanism, the
actual amount ofmode-of-action information
provided bythis approach is quite minimal.
All four of the above studies were con-
ducted using male mice. Other researchers
using female B6C3F1 mice found very few
codon 61 H-ras mutations in tumors from
DCA-treated animals (74). Therefore, it is
clear that codon 61 H-ras mutation is cer-
tainly not required forliver tumorformation.
As stated above, the approach used in
these studies is not likely to yield definitive
mode-of-action information. The male
B6C3F1 hybrid used in these studies has a
high occurrence (approximately 40%) (72)
ofspontaneous hepatocellular neoplasms.
This makes it impossible to distinguish spon-
taneously arising tumors from chemically
induced tumors. Furthermore, the analysis of
mutational spectra at any three base pair
codon, where spontaneous mutation occurs,
lacks the resolving power needed to deter-
mine whether the mutations seen are sponta-
neous or induced. Full utilization of the
power of mutational spectral information
requires the analysis ofentire genes or sub-
stantial portions ofgenes. In addition, the
most information is obtained by a two-
pronged approach that includes both an
analysis ofmutations in oncogenes or tumor-
suppressor genes in tumor tissue and the
determination of the full array ofpossible
mutations that can be induced by the chemi-
cal being evaluated. This evaluation ofthe
full array ofpossible miutations requires the
use ofa target gene that can be mutated by
the chemical and can display all the possible
mutations that the chemical can induce.
Concordance between mutations observed
in cancer-relevant genes in tumor tissue and
possible mutations that can be induced by
the chemical provides evidence (but does
not prove) that the chemical is causing
tumors by a mutational mechanism. Such
studies have not been done for TCE or any
ofits metabolites.
Ofcourse, the key questions are whether
TCE can induce tumors in humans and
whether those tumors are induced through a
mutational mode of action. A group of
German researchers are trying to address this
issue by evaluating the spectrum of
mutational events seen in the von Hippel-
Lindau (VHL) gene ofrenal cell carcinomas
from people who have been exposed to high
levels ofTCE (75,76). Like the studies in
rodents, the pattern ofmutations found by
these researchers appears to be different in
tumor tissue taken from people exposed and
not exposed to TCE. Unlike the rodent
studies discussed above, these investigators are
sequencing large numbers ofbase pairs and
thus may be able to identify specific muta-
tional patterns in tumnors from individuals
exposed to TCE. However, aswith all human
studies, the subjects ofthese investigations
likely were occupationally exposed to a vari-
ety ofchemicals, which makes any definitive
determination difficult.
Recently, this research group (76) has
found what appears to be a specific muta-
tional hot spot at nucleotide 454 in the VHL
gene ofrenal cell carcinomas from individuals
occupationally exposed to TCE. In this study
the paraffin-embedded tumor tissue from 44
people with renal cell carcinoma and known
exposure to TCEwere evaluated. VHL muta-
tions were found in 33 (75%) ofthe cases.
Often there were multiple mutations and also
loss ofheterozygosity ofthe VHL gene. The
nucleotide 454 mutation was seen in 13
(39%) ofthe cases. In addition, this same
mutation was present in adjacent nonneoplas-
tic kidney parenchyma in 4 ofthese patients.
This implies that this mutation occurred
rather early in the etiology ofthe tumors in
these 4 patients. The TCE-exposed individu-
als were compared to 107 renal cell carci-
noma patients who had no known TCE
exposure. While VHL mutations were
observed in the tumor tissue ofpeople not
known to be exposed to TCE, none ofthese
mutations occurred at nucleotide 454. While
this study does not prove that TCE induced
Table 1. Mutation analysis of codon 61 (CAA) in H-ras
of liver tumors from B6C3F1 male mice treated with TCE
or its metabolites.
Total
mutations, AM CGA CTA
no. No. % No. % No. %
Control 77 48 62 20 26 8 10
DCA 62 15 24 25 40 22 35
TCA 5 4 80 1 20 0 0
TCE 42 12 29 10 24 17 40
Combined data ofAnna etal.(711 andFerreira-Gonzalez etal.(65).
Table 2. Mutation analysis of codon 61 (CAA) in H-ras
of liver tumors from untreated B6C3F1 mice.
Total
mutations, AAA
no. No. %
Female 33 17 52
Male 177 106 60
Data from Maronpot et al. 172,73).
CGA
No. %
12 36
50 28
CTA
No. %
4 12
21 12
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the VHL mutations in these individual, these
data are particularly intriguing and do suggest
a potential role for TCE in the etiology ofthe
VHLgene alterations.
Summary Evaluation
From the available data, it is clear that TCE
and its metabolites are not potent genotoxic
agents. When compared with other genotoxic
or mutagenic agents in a number ofdifferent
test systems, both in vitro and in vivo, the
results (Figures 1-7) consistently show that
TCE and its metabolites (with the exception
ofDCVC) are weakly genotoxic and require
high doses to induce a response. The concen-
trations required to attain positive responses
in the various in vitro and, where information
is available, in vivo assays are much higher
(orders ofmagnitude higher) than one would
expect to see, in vivo, in any possible target
tissue. We interpret this body ofevidence to
suggest that most ofthe genotoxic activity of
these chemicals (with the exception of
DCVC) is likely due to mechanisms that
occur only at relatively high concentrations-
levels that would not be attained in vivo.
Therefore, we feel it is unlikely that these
chemicals would be mutagenic, at any target
tissue, at exposure levels that are relevant to
humans. When all of the information con-
cerning the genotoxic potential for TCE and
its metabolites is taken together, it appears
unlikely that TCE could induce tumors
through a mutagenic mode ofaction.
Unfortunately, however, we cannot elimi-
nate the possibility that chemically induced
mutation is a keyevent in the development of
TCE-induced tumors. DCVC does cause
point mutations, at least in bacteria. It is
unfortunate that so little data are available for
this chemical. It is not dear whether the rela-
tively potent (compared to the other TCE
metabolites) response seen in vitro in
Salmonella would also be observed in an in
vivoassay.
Also, as indicated earlier, the key questions
are whether the human tumors associated
with TCE exposure are in fact induced by
TCE, and ifso, whether chemically induced
mutation is a key event in that tumor induc-
tion. While there is much research yet to be
done, the studies analyzing the kidney tumors
from humans with high exposure to TCE are
proving to be very interesting. However, if
TCE is capable ofinducing mutations, it is
surprising that the standard battery ofmuta-
tion assays is unable to detect this mutagenic-
ity. Further studies, including studies to
elucidate all the possible types ofmutations
that may be induced by TCE (or TCE
metabolites-particularly DCVC) should pro-
vide significant new information. Further
investigation oftrichloroethanol and the other
relevant trichloroethylene conjugates is also
required. These studies combined with the
human investigations should provide substan-
tial new information that may change the
conclusions that we have drawn concerning
whether chemically induced mutation is
likely to be a key event in the etiology of
TCE-induced tumors.
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